Tag:
GlaxoSmithKline
Latest Headlines
Latest Headlines
Index Ventures taps Big Pharma-backed fund to hatch anticoagulant upstart
With an experimental therapy that could save "millions of lives," biotech startup XO1 Ltd. said it has raised $11 million in a Series A round of financing from Index Ventures.
UPDATED: GlaxoSmithKline slams brakes on trial of MS drug linked to data scandal
GlaxoSmithKline has stopped development of an experimental drug for multiple sclerosis after a preclinical study turned out to contain "misrepresentations" in data from its R&D labs in China.
UPDATED: GSK probes sales tactics in China days after firing R&D chief there
Novartis acknowledged this week it had terminated some sales execs in India as it probes unethical practices there, and now GlaxoSmithKline admits it is looking into whether its sales folks have been bribing doctors in China.
Glaxo's dismissed China R&D chief fires back
GlaxoSmithKline fired Jingwu Zang after allegations that the R&D shop he helmed in China published falsified data. Yet Zang has fired back in a report from The Wall Street Journal, saying that he played a supervisory role and had no part in the actual misrepresentations that appeared in a 2010 issue of Nature Medicine .
FDA clears Sanofi to compete for 4-in-1 flu vaccine market
The 2013-14 flu season is set to be the most closely watched in years. In February, FDA cleared the use of quadrivalent vaccines which protect against two A and two B strains. GlaxoSmithKline and AstraZeneca began gearing up, and Sanofi will now join them too.
Latin American cancer vax races Big Pharma rivals
The lung cancer vaccine race has brought together an unusual mix of players. Merck KGaA was in a good position, but its vaccine disappointed in Phase III, while GlaxoSmithKline could report data on its candidate this year. Then there is the Cuba-Argentina joint venture.
GlaxoSmithKline's research chief in China fired for data fraud
The head of GlaxoSmithKline's R&D operation in China has been fired while another researcher has resigned following a company probe into allegations that data on interleukin-7 research published in Nature Medicine was "misrepresented" by company researchers.
UPDATED: FDA advisers vote for looser reins on GlaxoSmithKline's Avandia
It took multiple tries and a vote tallied on paper to make sure everything was correct, but finally, we have a verdict. After two days of hearings, on Thursday an advisory panel recommended the FDA keep Avandia on the market and ease restrictions on its use.
GlaxoSmithKline investigates alleged data fraud involving R&D lab staffers in China
GlaxoSmithKline has launched a probe of a research study involving its employees from a research lab in Shanghai, China.
FDA official, panelists challenge Avandia safety trial
Dr. Thomas Marciniak, medical team leader of FDA's Division of Cardiovascular and Renal Products, made some expensive promises Wednesday morning before a panel of outside experts tasked with advising the FDA on whether to lift current restrictions on GlaxoSmithKline's diabetes drug Avandia.
